Dossier assessment
Necitumumab - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Necitumumab - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Necitumumab - Benefit assessment according to §35a Social Code Book V
Press releases
Necitumumab in NSCLC: indication of minor added benefit for patients with metastases
Disadvantages in side effects do not outweigh advantage in overall survival
Additional information
Federal Joint Committee (G-BA)
2016-09-15 A G-BA decision was published.
Project details
- Project no.
- A16-17
- Commission
- Commission awarded on 30.03.2016 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
The current version 1.1 of the dossier assessment replaces version 1.0 published on 1 July 2016.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.